IGF2BP1 with high expression in stomach adenocarcinoma (STAD), enhanced the growth and metastasis of GC in vivo, which exerts an oncogenic role in GC through enhancing the glycolytic enzyme c-Myc. Here, IGF2BP1 is linked to gastric adenocarcinoma.